Escherichia coli Nissle 1917 anti-tumor targeting engineering bacterium as well as construction method and application thereof

By constructing the E. coli Nissle 1917 anti-tumor targeted engineering bacteria EcN (PTEN), the difficulties in the expression and secretion of anti-tumor proteins in bacterial targeting technology were solved, and efficient, safe and accurate tumor targeting effects were achieved, significantly inhibiting tumor cells. Grow and ensure biosafety.

CN119020252AInactive Publication Date: 2024-11-26QIANSHENG (SHENZHEN) KECHUANG GRP CO LTD +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411217062.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-02
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing bacterial targeting technologies have targeting and toxicity problems in tumor treatment, making it difficult to ensure efficient, safe, and precise expression and secretion of anti-tumor proteins, especially while maintaining spatial structure and activity.

Method used

EcN (PTEN), an anti-tumor targeted engineered bacteria of E. coli Nissle 1917, was constructed, and soluble and secretory expression of PTEN protein was achieved by designing oligonucleotide primers, PTEN protein-induced expression vectors, hypoxia expression promoters and prosoluble tags. And transfer it to E. coli by overlapping PCR technology to ensure targeting and biosafety.

Benefits of technology

The eukaryotic anti-tumor protein PTEN is stable, efficient and secretly expressed in E. coli, which significantly inhibits tumor cell growth, is highly efficient, targeted, safe and economical, and the tumor suppression rate reaches 60.76%, and there is no Toxic side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020252A_ABST
    Figure CN119020252A_ABST
Patent Text Reader

Abstract

The invention relates to an Escherichia coli Nissle 1917 anti-tumor targeting engineering bacterium and a construction method and application thereof, the Escherichia coli Nissle 1917 anti-tumor targeting engineering bacterium is named as Escherichia coli Nissle 1917 (PTEN), is preserved in the China Center for Type Culture Collection on June 25, 2023, has a strain preservation number of CCTCC NO: M 20231089, and is classified and named as Escherichia coli EcN (PTEN), and the Latin name of the Escherichia coli EcN (PTEN) is Escherichia coli EcN (PTEN). The invention also comprises a construction method of the Escherichia coli Nissle 1917 anti-tumor targeting engineering bacterium and an application of the Escherichia coli Nissle 1917 anti-tumor targeting engineering bacterium in preparation of anti-tumor targeting drugs. The Escherichia coli anti-tumor targeting engineering bacterium can express the anti-tumor protein PTEN in a soluble and secretory manner, can stably express the anti-tumor protein PTEN in a tumor position, and can express the anti-tumor protein PTEN in a secretory manner, so that a good anti-tumor effect is achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to an Escherichia coli Nissle 1917 anti-tumor targeted engineering bacterium and a construction method and application thereof, in particular to the application of the construction of an Escherichia coli Nissle 1917 anti-tumor targeted engineering bacterium in the preparation of targeted anti-tumor drugs. Background Art

[0002] As a miniature "biological factory", bacteria can sense changes in the external environment at any time according to their own physiological and metabolic characteristics, constantly change the direction of movement, and finally selectively colonize at the tumor site. At present, bacteria play an important role in cancer treatment by using their specific targeting to release their natural toxicity to the tumor site, express anticancer drugs, genes, carry nanomedicines, highly lethal therapeutic proteins, etc. The oxygen concentration in normal mammalian tissue is about 2% to 9%, but because tumor cells use high metabolism to consume high oxygen and inhibit angiogenesis in the surrounding environment, the oxygen concentration in the tumor microenvironment is reduced to a hypoxic state (O2 <0.02%). A series of studies have shown that bacterial treatment of cancer generally shows a significant reduction or disappearance of tumor volume, an increase in survival rate, and a decrease in tumor metastasis and tumor recurrence rate. It is a cancer treatment method with great potential. Previous studies have found that many bacteria, such as Salmonella, Escherichi, Clostridium, Caulobacter, Listeria, Proteus, and Streptococcus, preferentially colonize and accumulate at tumor sites.

[0003] The results of the study confirmed that the intestinal probiotic Escherichia coli Nissle 1917 (EcN) strain has low toxicity, specific tumor colonization ability, excellent tumor tissue penetration ability and real-time monitoring. The above advantages of the bacteria make Escherichia coli Nissle 1917 likely to efficiently and stably secrete anti-tumor proteins at the tumor site, and it is a tumor treatment method with good application prospects in the future. However, there are still certain defects based on the particularity of bacteria. The targeting and toxicity of some bacteria may cause the treated body to be infected and reduce the treatment effect. Based on this, ensuring the biosafety and precise targeting of anti-tumor targeted engineered bacteria has become an urgent problem to be solved. At the same time, after ensuring the precise targeting of Escherichia coli EcN to solid tumors, how to efficiently and solublely express eukaryotic anti-tumor proteins in bacterial engineered bacteria and maintain normal spatial structure and activity is also another difficulty that needs to be solved in the application of bacterial treatment of tumors. Summary of the invention

[0004] The technical problem to be solved by the present invention is to overcome the above-mentioned defects of the prior art and provide an anti-tumor targeting engineered bacterium of Escherichia coli Nissle1917 and a construction method and application thereof.

[0005] The Escherichia coli Nissle 1917 anti-tumor targeted engineered bacteria of the present invention can achieve stable, efficient and secretory expression of the eukaryotic anti-tumor protein PTEN in Escherichia coli. The present invention can construct an anti-tumor targeted engineered bacteria with "four highs" of high efficiency, targeting, safety and economy.

[0006] The technical solution adopted by the present invention to solve the technical problem is as follows:

[0007] The Escherichia coli Nissle 1917 anti-tumor targeted engineered bacteria of the present invention, namely Escherichia coli Nissle1917 (PTEN), abbreviated as EcN (PTEN), was deposited in the China Center for Type Culture Collection on June 25, 2023, with the strain collection number of CCTCC NO: M 20231089, and the classification name is: Escherichia coli EcN (PTEN), and the Latin name is Escherichiacoli EcN (PTEN).

[0008] The method for constructing the anti-tumor targeting engineered bacterium Escherichia coli Nissle 1917 of the present invention mainly comprises the following steps:

[0009] (1) Based on the phosphatase and tensin homolog PTEN gene sequence with accession number AF067844.1 registered in Genbank, a pair of oligonucleotide chains were designed as primers, and the PTEN gene was amplified using the cDNA of human embryonic kidney cells HEK293T as a template;

[0010] (2) Construction and identification of PTEN inducible expression vector;

[0011] (3) Inducible expression, purification and activity identification of PTEN protein;

[0012] (4) Construction of Escherichia coli anti-tumor targeted engineered bacteria EcN (PTEN).

[0013] The method for constructing the anti-tumor targeting engineered bacterium Escherichia coli Nissle 1917 of the present invention may further include the following steps:

[0014] (5) Analysis of EcN colonization in tumor-bearing mice;

[0015] (6) Anti-tumor analysis of Escherichia coli anti-tumor targeted engineered bacteria EcN (PTEN);

[0016] (7) Biosafety testing of the Escherichia coli anti-tumor targeted engineered bacteria EcN (PTEN).

[0017] The Escherichia coli anti-tumor targeting engineering bacteria constructed by the present invention expresses phosphatase and tensin homolog PTEN in a soluble and secretory manner and can specifically target the hypoxic microenvironment of the tumor.

[0018] The present invention uses the Genbank database to search for the gene sequence of PTEN protein, and designs oligonucleotide primers based on this, and successfully clones the cDNA from human embryonic kidney cells HEK293T. It is cloned into three different expression vectors and transferred into Escherichia coli BL21 (DE3) for induced expression. Protein solubility analysis shows that PTEN protein is efficiently soluble under the SUMO tag, while the soluble expression amount is low under the IF2 tag. At the same time, it is purified by HPLC nickel column, and the in vitro activity of PTEN protein is detected.

[0019] Further, in step (4), the step of constructing the Escherichia coli anti-tumor targeted engineered bacteria EcN (PTEN) is to insert the hypoxia expression promoter P vhb , SUMO (protein is represented by "SUMO" and gene is represented by "somo") soluble tag, anti-tumor gene pten, were amplified by overlapping PCR technology to become a PCR product with three segments, and then transferred to the expression vector pET-28a by enzyme digestion and enzyme ligation method, and heat-transferred into Escherichia coli Nissle 1917 (the Chinese name is Escherichia coli Nissle1917, Escherichia coli Nissle 1917 was donated by Professor Zhang Youming of the State Key Laboratory of Microbiology, Shandong University), and the Escherichia coli anti-tumor targeted engineered bacteria EcN (PTEN) were obtained.

[0020] SEQ ID №1: pten gene sequence:

[0021] ATGAC AGCCATCATC AAAGAGATCG TTAGCAGAAA CAAAAGGAGA TATCAAGAGGATGGATTCGA CTTAGACTTG

[0022] ACCTATATTT ATCCAAACAT TATTGCTATG GGATTTCCTG CAGAAAGACT TGAAGGCGTATACAGGAACA

[0023] ATATTGATGA TGTAGTAAGG TTTTTGGATT CAAAGCATAA AAACCATTAC AAGATATACAATCTTTGTGC

[0024] TGAAAGAGAT TATGACACCG CCAAATTTAA TTGCAGAGTT GCACAATATC CTTTTGAACCATAACCCA

[0025] CCACAGCTAG AACTTATCAA ACCCTTTTGT GAAGTCTTG ACCAATGGCT AAGTGAAGATGACATCATG

[0026] TTGCAGCAAT TCACTGTAAA GCTGGAAAGG GACGAACTGG TGTAATGATA TGTGCATATTTATTACATCG

[0027] GGGCAAATTT TTAAAGGCAC AAGAGGCCCT NATIONALTTCTAT GGGGAAGTAA GGACCAAAAAAAGGGA

[0028] GTAACTATTC CCAGTCAGAG GCGCTATGTG TATTATTA GCTACCTGTT AAAGAATCATCTGGATTATA

[0029] GACCAGTGGC ACTGTTGTTT CACAAGATGA TGTTTGAAAC TATTCCAATG TTCAGTGGCGGAACTTGCAA

[0030] TCCTCAGTTT GTGGTCTGCC AGCTAAAGGT GAAGATATAT TCCTCCAATT CAGGACCCCACACGACGGGAA

[0031] GACAAGTTCA TGTACTTTGA GTTCCCTCAG CCGTTACCTG TGTGTGGTGA TATCAAAGTAGAGTTCTTCC

[0032] AAAACAGAA CAGATGCTA AAAAAGCACA AAATGTTTCA CTTTTGGGTA AATACATTCTTCATACCAGG

[0033] ACCAAGGAA ACCTCAGAAA AAGTAGAAAAA TGGAAGTCTA TGTGATCAAG AAATCGATAGCATTTGCAGT

[0034] ATAGAGCGTG CAGATAATGA CAAGGAATAT CTAGTACTTA CTTTAACAAA AAATGATCTTGACAAAGCAA

[0035] ATAAAGACAA AGCCAACCGA TACTTTTCTC CAAATTTTAA GGTGAAGCTG TACTTCACAAAAACAGTAGA

[0036] GGAGCCGTCA AATCCAGAGG CTAGCAGTTC AACTTCTGTA ACACCAGATG TTAGTGACAATGAACCTGAT

[0037] CATTATAGAT ATTCTGACAC CACTGACTCT GATCCAGAGA ATGAACCTTT TGATGAAGATCAGCATACAC

[0038] AAATTACAAA AGTCTGA

[0039] SEQ ID№2: Hypoxia-expressed promoter Pvhb gene sequence:

[0040] TAGCTTACAG GACGCTGGGG TTAAAAGTAT TTGAGTTTTG ATGTGGATTA AGTTTTAAGAGGCAATAAAG

[0041] ATTATAATAA GTGCTGCTAC ACCATACTGA TGTATGGCAA AACCATAATA ATGAACTTAAAGAGGAAGAT AT SEQ ID№3: Solubilizing tag somo gene sequence:

[0042] ATGACAGATG TAACGATTAA AACGCTGGCC GCAGAGCGAC AGACCTCCGT GGAACGCCTGGTACAGCAAT

[0043] TTGCTGATGC AGGTATCCGG AAGTCTGCTG ACGACTCTGT GTCTGCACAA GAGAAACAGACTTTGATTGA

[0044] CCACCTGAAT CAGAAAAATT CAGGCCCGGA CAAATTGACG CTGCAACGTA AAACACGCAGCACCCTTAAC

[0045] ATTCCTGGTA CCGGTGGAAA AAGCAAATCG GTAAAATCG AAGTCCGCAA GAAACGCACCTTTGTGAAAC

[0046] GCGATCCGCA AGAGGCTGAA CGCCTTGCAG CGGAAGAGCA AGCGCAGCGT GAAGCGGAAGAGCAAGCCCG

[0047] TCGTGAGGCA GAAGAATCGG CTAAACGCGA GGCGCAACAA AAAGCTGAAC GTGAGGCCGCAGAACAAGCT

[0048] AAGCGTGAAG CTGCTGAACA AGCGAAACGT GAAGCTGCGG AAAAAGACAA AGTGGAAAACCTGTATTTTC AG

[0049] The bacterial cells and culture medium supernatant after fermentation of the Escherichia coli anti-tumor targeting engineered bacteria EcN (PTEN) of the present invention were subjected to SDS-PAGE and Western blot detection, and the results showed that PTEN had successfully achieved soluble and secretory expression.

[0050] Wild-type EcN was injected into CT26 colorectal cancer BALB / c mice, and the in vivo imaging system observed that EcN could colonize in the hypoxic area of ​​the tumor, but not in other organs. Immunohistochemistry results also showed that PTEN protein was successfully expressed in solid tumors.

[0051] The Escherichia coli anti-tumor targeted engineered bacteria EcN (PTEN) of the present invention was used to treat CT26 colorectal cancer BALB / c mice. The results showed that the anti-tumor targeted engineered bacteria could significantly inhibit the growth of tumor cells in mice, and the tumor inhibition rate of CT26 colorectal cancer BALB / c mice was as high as 60.76%.

[0052] The Escherichia coli anti-tumor targeted engineering bacteria of the present invention has the following advantages:

[0053] 1. Carrying the hypoxia expression vector pET28a-Pvhb-pelB-PTEN, the anti-tumor protein PTEN can be expressed soluble and secreted.

[0054] 2. The Escherichia coli anti-tumor targeting engineered bacteria EcN (PTEN) of the present invention can stably express and secrete the anti-tumor protein PTEN at the tumor site, exerting a good anti-tumor effect.

[0055] The present invention can construct an anti-tumor targeting engineered bacterium with "four highs" of high efficiency, targeting, safety and economy. The Escherichia coli Nissle 1917 anti-tumor targeting engineered bacterium of the present invention can achieve stable, efficient and secretory expression of the eukaryotic anti-tumor protein PTEN in Escherichia coli.

[0056] Compared with existing anti-tumor drugs, the Escherichia coli anti-tumor targeted engineered bacteria EcN (PTEN) of the present invention has the following advantages:

[0057] (1) Anti-tumor effect: Escherichia coli anti-tumor targeted engineered bacteria EcN (Tum-5) has a significant anti-tumor effect on mice bearing colorectal cancer. The experiment showed that the inhibition rate of tumor volume and weight can be as high as 60.76% and 62.29% respectively.

[0058] (2) No toxic side effects: After tumor-bearing mice were injected with E. coli anti-tumor targeted engineered bacteria EcN (PTEN), there were no significant changes in the weight, liver, spleen, kidney weight, and tissue morphology of the mice compared with other treatment groups. Safety to the environment: E. coli Nissle 1917 is an intestinal probiotic with low toxicity. It has been used as a probiotic for gastrointestinal treatment.

[0059] Description of Microbiological Deposit

[0060] The Escherichia coli Nissle 1917 anti-tumor targeted engineered bacteria of the present invention, namely Escherichia coli Nissle1917 (PTEN), abbreviated as EcN (PTEN), was deposited in the China Center for Type Culture Collection (CCTCC for short, address: Wuhan University, Wuhan, China) on June 25, 2023, with the strain collection number of CCTCC NO: M 20231089, and the classification name is: Escherichia coli EcN (PTEN), and the Latin name is Escherichia coli EcN (PTEN). BRIEF DESCRIPTION OF THE DRAWINGS

[0061] Figure 1 This is the electrophoresis pattern of the PCR product of the pten gene;

[0062] Figure 2 It is the construction and identification map of three inducible expression vectors in E.coil GB2005;

[0063] Figure 3 It is the soluble expression profile of PTEN protein detected by SDS-PAGE;

[0064] Figure 4 It is the spectrum of PTEN protein purified by Ni column detected by SDS-PAGE;

[0065] Figure 5 It is the Western Blot detection of PTEN protein profile;

[0066] Figure 6 This is a graph showing the in vitro activity detection of PTEN protein;

[0067] Figure 7 It is a map of PTEN protein inhibiting the migration of CT26 colorectal cancer cells in vitro;

[0068] Figure 8 is a flow chart of the construction of the recombinant plasmid pET28a-Pvhb-pelB-PTEN;

[0069] Fig. 9 is the PCR amplification of pten and sumo-pten fragments;

[0070] Fig.10 is the overlapping PCR amplification Pvhb-sumo-pten fragment map;

[0071] Fig.11 It is the double enzyme digestion identification map of pET28a-Pvhb-pelB-PTEN in E.coil GB2005;

[0072] Fig.12 It is a graph showing the expression of SUMO-PTEN protein in the engineering bacteria of the present invention detected by SDS-PAGE;

[0073] Fig.13 It is a graph of the expression of SUMO-PTEN protein in the engineering bacteria of the present invention detected by Western Blot;

[0074] Fig.14 This is a picture showing the localization of EcN in BALB / c mice bearing colorectal cancer, as observed by the small animal in vivo imaging system;

[0075] Fig.15 This is the distribution map of EcN in the organs of BALB / c mice bearing colorectal cancer;

[0076] Fig.16 This is a diagram showing the expression of PTEN protein in mouse tumor tissues detected by immunohistochemistry;

[0077] Fig.17 This is a graph showing the effect of the anti-tumor targeted engineered bacteria EcN (PTEN) on tumor inhibition and tumor size in BALB / c mice bearing colorectal cancer;

[0078] Fig.18 This is a picture of H&E staining to observe the effect of bacteria on mouse tumors, liver, kidney and spleen;

[0079] Fig.19 This is a graph showing the effect of the anti-tumor targeted engineered bacteria EcN (PTEN) on the body weight and weight of tumor, liver, kidney, and spleen of BALB / c mice bearing colorectal cancer; A represents the weight of tumors in different treatment groups after the end of treatment; B represents the weight change trend of mice in different treatment groups during the treatment process; C represents the weight of the liver, spleen, and kidney, the main immune organs of mice, after the end of treatment;

[0080] Fig. 20 This is a diagram showing the effect of the anti-tumor targeted engineered bacteria EcN (PTEN) on T lymphocytes, M1 macrophages, and neutrophils in the tumor microenvironment after treatment of BALB / c mice bearing colorectal cancer by immunohistochemistry;

[0081] Fig.21 This is a graph showing the effects of alanine aminotransferase and urea nitrogen detection on colorectal cancer-bearing BALB / c mice treated with tumor-targeted engineered bacteria EcN (PTEN);

[0082] Fig. 22 This is a graph showing the effects of qPCR detection of tumor-targeted engineered bacteria EcN (PTEN) on IL-6, IL-10, TNF, and MIF in BALB / c mice bearing colorectal cancer after treatment. DETAILED DESCRIPTION

[0083] The present invention is further described in detail below in conjunction with the accompanying drawings and embodiments.

[0084] The strains and plasmids used in the examples of the present invention are shown in Table 1, and the primers used are shown in Table 2.

[0085] Table 1 Strains and plasmids used in the present invention

[0086]

[0087]

[0088] Table 2 Primers used in the present invention

[0089]

[0090] The Escherichia coli Nissle 1917 anti-tumor targeted engineered bacteria of this embodiment, namely Escherichia coli Nissle 1917 (PTEN), abbreviated as EcN (PTEN), was deposited in the China Center for Type Culture Collection on June 25, 2023, with the strain collection number of CCTCC NO: M 20231089, and the classification name is: Escherichia coli EcN (PTEN), and the Latin name is Escherichia coli EcN (PTEN).

[0091] The method for constructing the anti-tumor targeted engineered bacterium Escherichia coli Nissle 1917 in this embodiment mainly includes the following steps:

[0092] (i) Based on the phosphatase and tensin homolog PTEN gene sequence with accession number AF067844.1 registered in Genbank, a pair of oligonucleotide chains were designed as primers, and the PTEN gene was amplified using the cDNA of human embryonic kidney cells HEK293T as a template;

[0093] PCR to obtain the gene pten: Culture human embryonic kidney cells HEK293T, and when the cells are 80% confluent, extract the total RNA of the cells, reverse transcribe the cDNA, and use it as a template to amplify the target gene pten (see Figure 1 , Figure 1 is the electrophoresis pattern of the PCR product of the pten gene).

[0094] (II) Construction and identification of three PTEN inducible expression vectors

[0095] The strain containing the empty plasmid was activated overnight, and then the relevant empty plasmid was extracted using a kit. The three empty plasmids pET28a, pSmartI, and pSmartII were digested with two enzymes, BamH I and Hind III. At the same time, the target gene containing the restriction site was digested with the same enzyme, and then gel recovery and PCR product purification were performed. The enzyme ligation system of the purified product was configured with a ratio of 7:1:1:1 of target gene: vector: T4 ligase: enzyme ligation buffer, and the enzyme ligation was performed at 22°C. The enzyme ligation product was introduced into E. coli DH5α by heat shock transformation, and then single clones were screened in LB solid culture medium containing kanamycin (50 μg / mL). The screened single clones were expanded and cultured, and the recombinant plasmids were extracted for PCR and double enzyme digestion identification. The correct recombinant plasmids were sent to Shanghai Biotechnology for sequencing identification. In this experiment, three protein expression plasmids were constructed: pET28a-PTEN, pSmartI-PTEN (containing SUMO soluble tag protein), and pSmarII-PTEN (containing IF2 domain I soluble tag protein). Figure 2This is the construction and identification map of three inducible expression vectors in E.coil GB2005).

[0096] (III) Inducible protein PTEN expression, purification and activity identification

[0097] 1. Analysis of PTEN protein solubility

[0098] Extract the correctly constructed recombinant plasmid. Introduce it into E.coli BL21 (DE3) competent cells through heat shock transformation to obtain three different protein induced expression strains, which are named E.coli BL21 (DE3) / pET28a-PTEN, E.coli BL21 (DE3) / pSmartI-PTEN, E.coli BL21 (DE3) / pSmartII-PTEN. Take the three induced expression strains, pick an appropriate amount of the bacterial preservation solution and add it to 20mL of LB selection medium containing kanamycin (50μg / mL) for overnight activation. Transfer it to 50mL of fresh LB liquid culture medium at a volume ratio of 1%, and shake and culture it to its OD 600 0.4-0.6. Take two bottles of fresh bacterial solution and set them as experimental group and control group respectively. Add 5μL IPTG to the experimental group and no IPTG to the control group. After culturing for 4 hours, collect 1mL of bacterial solution in an EP tube, centrifuge to remove the supernatant, wash the bacteria twice with PBS, and finally add an appropriate amount of pre-cooled PBS for suspension. Break the cells at low temperature on ice, collect the supernatant and precipitate by centrifugation, and dissolve the precipitate with an appropriate amount of PBS. SDS-PAGE was used to detect the collected supernatant and precipitate ( Figure 3 is the soluble expression profile of PTEN protein detected by SDS-PAGE).

[0099] 2. Purification and Western Blot Detection of PTEN Protein

[0100] The bacterial suspension induced by the inducer was centrifuged to collect the precipitate. PBS was added to suspend the bacteria and ultrasonically disrupted at 400W. The supernatant was collected, sterilized using a 0.22μm filter, and purified on a Ni column. The Ni column was rinsed with 20% anhydrous ethanol and 5 volumes of sterile distilled water, and then the Ni column was balanced with buffer. The protein-containing supernatant was placed in the Ni column for adsorption for 20 minutes, and the target protein was washed from the column with different concentrations of imidazole eluents in turn. The most suitable imidazole concentration for washing the protein was determined for subsequent protein purification and in vitro activity assay of PTEN protein ( Figure 4The figure is the SDS-PAGE detection of Ni column purified PTEN protein spectrum). Anti-6×His polyclonal antibody was selected as the primary antibody for the experiment, and Western Blot was used to detect the soluble expression of PTEN protein in E.coil BL21(DE3) / pSmartI-PTEN engineering bacteria under both induced and non-induced conditions ( Figure 5 ).

[0101] 3. Identification of PTEN protein activity in vitro

[0102] The purified and quantified PTEN protein was adjusted to 10μg / mL, 7.5μg / mL, 5μg / mL, 2.5μg / mL, and 1μg / mL using PBS buffer, and acted on tumor cells CT26 and Hela in the logarithmic growth phase, respectively. After 24 hours, three different cell fields were selected to observe the number of living cells, and the PBS group was compared and the cell survival rate was calculated ( Figure 6 is the in vitro activity detection graph of PTEN protein). In order to further study whether it affects the migration of CT26 cells. 100 μL of 10 μg / mL purified PTEN protein was added to CT26 cells in the logarithmic growth phase, and the cells were observed under a microscope in the same field of view at 0h, 6h, 12h and 24h. Finally, the relevant migration rate was calculated ( Figure 7 PTEN protein inhibits the migration of CT26 colorectal cancer cells in vitro).

[0103] (IV) Construction of hypoxia expression vector

[0104] First, the PCR technique was used to clone the gene containing the hypoxia promoter P vhb The sequence was amplified to obtain the gene fragment Pvhb-pelB. Then, pSmartI-PTEN was used as a template, SUMO and PTEN-Hind III were used as upstream and downstream primers to amplify PTEN with a SUMO fusion tag to obtain the fusion gene fragment sumo-pten ( Fig. 9 PCR amplification of pten and sumo-pten fragments). After PCR product purification of these two fragments, the fusion fragment Pvhb-pelB-sumo-pten ( Fig.10 is the overlapping PCR amplification Pvhb-sumo-pten fragment map). After double digestion with Apa I+Hind III, it was connected to the pET28a expression vector ( Fig.11 The double enzyme digestion identification map of pET28a-Pvhb-pelB-PTEN in E.coil GB2005) was successfully constructed to construct the hypoxia expression vector pET28a-Pvhb-pelB-PTEN (the plasmid construction flow chart is shown in Figure 8The amplification procedure of the fusion fragment Pvhb-pelB-sumo-pten was 95°C pre-denaturation for 5 min, 95°C denaturation for 30 s, 68°C annealing for 30 s, 72°C extension for 1.5 min, 30 cycles, and finally 72°C extension for 10 min.

[0105] (V) Construction of anti-tumor targeted engineered bacteria expressing PTEN

[0106] Use a white pipette tip to streak the E.coli Nissle 1917 bacterial culture medium on LB solid medium. Pick a single clone and expand it in 20mL LB liquid medium. Then, electroporate the correctly constructed plasmid pET28a-Pvhb-pelB-PTEN containing hypoxia expression vector into E.coli Nissle 1917, pick a single clone, perform PCR verification, and obtain the anti-tumor targeted engineered bacteria EcN (PTEN).

[0107] (VI) Analysis of soluble and secretory expression of PTEN protein in EcN

[0108] Take the EcN (PTEN) strain and streak it on a resistance plate, select the positive clones, and transfer them to 20mL LB liquid culture medium for overnight expansion. Transfer it to 50mL liquid culture medium at 1% volume, culture it in an anaerobic environment for 8 hours, and then collect the supernatant and precipitate by centrifugation. Use the same method as above to extract protein from the culture fluid of EcN and EcN (pET28a) strains as the control group. At the same time, take 1mL of EcN (PTEN) culture medium supernatant, add 3mL of acetone containing 10% TCA, and keep it at -20℃ overnight to precipitate the protein. Centrifuge the precipitate and wash it with acetone 3 times. Dissolve it with 5×SDS Loading Buffer, and analyze it by SDS-PAGE and Western Blot ( Fig.12 , 13 , Fig.12 It is a graph showing the expression of SUMO-PTEN protein in the engineering bacteria of the present invention detected by SDS-PAGE; Fig.13 1 is a graph showing the expression of SUMO-PTEN protein in the engineering bacteria of the present invention detected by Western Blot).

[0109] (VII) Establishment of BALB / c mouse model bearing colorectal cancer

[0110] BALB / c mice were raised in an SPF animal room for 5 days to adapt to the corresponding environment. When the CT26 cells were cultured and about 80% of the cells were spread, they were digested with trypsin, washed three times with PBS buffer, suspended with DMEM medium, and the cell concentration was adjusted to 1×10 using a blood cell counting plate. 7The mice were stunned with isoflurane and 100 μL of diluted CT26 cells were injected into the axilla of the mouse forelimb to establish a CT26 cell mouse tumor model.

[0111] (VIII) Analysis of EcN (Tum-5) colonization in tumor-bearing mice

[0112] Overnight activation of fluorescent bacteria EcN (Lux), which contains the plasmid pET28a-LuxCDABE, a luciferase gene cluster from Photorhabditis elegans, can be performed at OD 600 After the CT26 tumor-bearing mice were successfully established, the EcN(Lux) cells were collected and the concentration was adjusted to 5×10 8 CFU / mL, injected into mice via intraperitoneal injection, the injection volume was 100μL. Then the corresponding EcN (Lux) colonization sites were observed in real time by IVIS. The mice were killed 10 days after injection, and the tumors, livers, kidneys, and spleens of the mice were separated. The distribution of EcN (Lux) was observed using a small animal in vivo imaging system ( Fig.14 , 15 , Fig.14 This is a picture showing the localization of EcN in BALB / c mice bearing colorectal cancer, as observed by the small animal in vivo imaging system; Fig.15 This is a diagram of the distribution of EcN in the organs of BALB / c mice bearing colorectal cancer). Fig.14 : IVIS results showed that after intraperitoneal injection, EcN (Lux) only appeared in the abdomen and tumor location of CT26 tumor-bearing mice. Fig.15 : Ten days after the injection, the tumor-bearing mice were killed, and the tumors, livers, kidneys, and spleens of the tumor-bearing mice were removed. It was found that only the tumor position showed EcN bioluminescence, and no fluorescence was observed in other organs. All of the above illustrate the specific targeting of EcN to tumor tissues.

[0113] (IX) Analysis of the anti-tumor effect of Escherichia coli anti-tumor targeted engineered bacteria

[0114] After the injection of CT26 cells, a soybean-sized mass of about 100 mm 3The mice were randomly divided into 4 groups, 3 mice in each group, as parallel groups. They were PBS group, EcN group, EcN(28a) group, and EcN(PTEN) group. The Chinese meanings of PBS group, EcN group, EcN(28a) group, and EcN(PTEN) group were intraperitoneal injection of PBS to treat tumor-bearing mice, injection of EcN to treat tumor-bearing mice, injection of EcN(28a) to treat tumor-bearing mice, and injection of EcN(PTEN) to treat tumor-bearing mice. The three strains of EcN(Escherichia coli Nissle1917), EcN(28a) (Escherichia coli Nissle 1917 containing the empty vector pET28a), and EcN(PTEN) (Escherichia coli Nissle 1917 containing the hypoxia expression vector pET28a-Pvhb-pelB-PTEN) were activated overnight, the cells were collected by centrifugation, and then washed with PBS. Finally, the concentration of the bacterial solution was adjusted to 5×10 7 CFU / mL, 100 μL of the corresponding bacterial solution was injected intraperitoneally every 5 days. After completing three injections, the experimental mice were killed. The tumor, liver, kidney, and spleen were retained for weight measurement (see Fig.19 C, represents the weight of the liver, spleen, and kidney, the main immune organs of mice after treatment), immunohistochemical physiological detection ( Fig.16 is the expression of PTEN protein in mouse tumor tissue detected by immunohistochemistry), H&E pathology detection ( Fig.18 This is a graph of the effects of bacteria on mouse tumors, liver, kidney and spleen observed by H&E staining). During the experiment, the tumor weight of the mice after treatment and the daily weight changes of the mice during treatment were measured (see Fig.19 A represents the weight of tumors in different treatment groups after treatment. Fig.19 B represents the weight change trend of mice in different treatment groups during the treatment process). The tumor size was measured by vernier calipers to determine the longest diameter and vertical maximum diameter of the tumor in mice. Fig.17 This is the tumor inhibition entity diagram and tumor size effect diagram of the anti-tumor targeted engineered bacteria EcN (PTEN) on BALB / c mice bearing colorectal cancer. Fig.19 c) Immunohistochemical physiological detection ( Fig.16 )、H&E pathology test( Fig.18 ) test results show that the Escherichia coli anti-tumor targeted engineered bacteria of the present invention has good biosafety. Fig.17 The test results showed that the tumor-bearing mice treated with engineered bacteria showed a strong tumor-suppressing effect. After the experiment, the size of the tumor was significantly smaller than that of the tumor-bearing mice treated with PBS.

[0115] Tumor size = longest diameter of the tumor × maximum vertical diameter of the tumor 2 / 2(Unit: mm 3 );

[0116] The inhibition rate of tumor volume = (tumor volume of control group - tumor volume of treatment group) / tumor volume of control group × 100%.

[0117] The inhibition rate was calculated (Table 3).

[0118] Total RNA from immune organ tissues was obtained, and after reverse transcription of cDNA, qRT-PCR was used to measure the expression levels of four immune factors, IL-2, IL-10, TNF, and MIF, in the liver, spleen, kidney and other organs of mice, with β-actin as the internal reference gene. Fig. 22 The qPCR detection of the effect of tumor-targeted engineered bacteria EcN (PTEN) on IL-6, IL-10, TNF, and MIF in BALB / c mice bearing colorectal cancer. At the same time, immunohistochemistry was used to analyze the effect of anti-tumor engineered bacteria EcN (PTEN) on T lymphocytes, M1 macrophages, and neutrophils in the tumor microenvironment of mice ( Fig. 20 This is an immunohistochemical test of the effect of anti-tumor targeted engineered bacteria EcN (PTEN) on T lymphocytes, M1 macrophages, and neutrophils in the tumor microenvironment after treatment of BALB / c mice bearing colorectal cancer). Finally, blood was collected from the tail vein of the tumor-bearing mice that completed the treatment, about 200 μL. The blood was allowed to stand to stratify, and the upper layer of serum was taken to measure urea nitrogen and alanine aminotransferase activity. Fig.21 This is a graph showing the effects of alanine aminotransferase and urea nitrogen detection on the tumor-targeted engineered bacteria EcN (PTEN) after treatment on BALB / c mice bearing colorectal cancer].

[0119] Fig. 22 :It shows that although there are up-regulation and down-regulation of gene expression of some inflammatory factors in different tissues, this just shows that during the treatment of engineered bacteria, the immune environment of the immune organs remains active, which may produce local micro-inflammatory reactions, but effectively recruiting phagocytes or lymphocytes can clear the small amount of engineered bacteria colonized in the immune organs, thereby protecting the organs from damage. At the same time, the slight upregulation of some inflammatory factors and the mild inflammatory reaction will not harm the tissues, which is a normal body reaction. This indirectly illustrates the biological safety of the constructed engineered bacteria EcN (PTEN). Fig.21 : Alanine aminotransferase is located in the liver and is often used as an important indicator for clinical evaluation of liver damage, and urea nitrogen is often used as an effective indicator for evaluating kidney function. The results showed that there was no significant difference between the EcN (PTEN) group and the PBS group, indicating that the engineered bacteria would not cause liver and kidney damage after treatment.

[0120] Table 3 Comparison of tumor volume and weight in BALB / c mice bearing colorectal cancer

[0121]

[0122] The results in Table 3 show that tumor-bearing mice treated with engineered bacteria EcN (PTEN) showed excellent tumor inhibition effects, with a volume inhibition rate of 60.76% (P < 0.01) and a weight inhibition rate of 62.29% (P < 0.05), both of which were significantly different from those in the PBS group.

[0123] Compared with existing anti-tumor drugs, the Escherichia coli anti-tumor targeting engineered bacteria EcN (PTEN) of the present invention has the following advantages:

[0124] The following advantages:

[0125] (1) Anti-tumor effect: Escherichia coli anti-tumor targeted engineered bacteria EcN (Tum-5) has a significant anti-tumor effect on mice bearing colorectal cancer. The experiment showed that the inhibition rate of tumor volume and weight reached 60.76% and 62.29% respectively.

[0126] (2) No toxic side effects: Tumor-bearing mice injected with E. coli anti-tumor targeted engineered bacteria EcN (PTEN)

[0127] Afterwards, there were no significant changes in the body weight, liver, spleen and kidney weights and tissue morphology of the mice compared with the other treatment groups. Safety to the environment: Escherichia coli Nissle 1917 is an intestinal probiotic with low toxicity and has been used as a probiotic for gastrointestinal treatment.

Claims

1. An anti-tumor targeted engineered bacterium of Escherichia coli Nissle 1917, characterized in that: It was named Escherichiacoli Nissle 1917 (PTEN), and was deposited in the China Center for Type Culture Collection on June 25, 2023. The strain collection number is CCTCC NO: M 20231089, and the classification name is: Escherichia coli EcN (PTEN), and the Latin name is Escherichia coli EcN (PTEN).

2. The Escherichia coli Nissle 1917 anti-tumor targeted engineered bacteria according to claim 1, characterized in that: The Escherichia coli Nissle 1917 anti-tumor targeted engineered bacteria can be targeted and colonized in the tumor hypoxic microenvironment and stably secrete the soluble anti-tumor protein PTEN.

3. A method for constructing the anti-tumor targeting engineered bacterium Escherichia coli Nissle 1917 as claimed in claim 1 or 2, characterized in that: The following steps are involved: (1) Based on the phosphatase and tensin homolog PTEN gene sequence with accession number AF067844.1 registered in Genbank, a pair of oligonucleotide chains were designed as primers, and the PTEN gene was amplified using the cDNA of human embryonic kidney cells HEK293T as a template; (2) Construction and identification of PTEN inducible expression vector; (3) Inducible expression, purification and activity identification of PTEN protein; (4) Construction of Escherichia coli anti-tumor targeted engineered bacteria EcN (PTEN).

4. The method for constructing the anti-tumor targeted engineered bacterium Escherichia coli Nissle 1917 according to claim 3, characterized in that: The following steps are also included: (5) Analysis of EcN colonization in tumor-bearing mice; (6) Anti-tumor analysis of Escherichia coli anti-tumor targeted engineered bacteria EcN (PTEN); (7) Biosafety testing of the Escherichia coli anti-tumor targeted engineered bacteria EcN (PTEN).

5. The method for constructing the anti-tumor targeted engineered bacterium of Escherichia coli Nissle 1917 according to claim 3 or 4, characterized in that: In step (4), the step of constructing the Escherichia coli anti-tumor targeted engineered bacteria EcN (PTEN) is to insert the hypoxia expression promoter P vhb , SUMO lytic tag, and anti-tumor gene pten were amplified by overlapping PCR technology to become a PCR product with three segments, which was then transferred to the expression vector pET-28a by enzyme digestion and ligation, and heat-transferred into Escherichia coli Nissle 1917 (Escherichia coli Nissle 1917) to obtain the Escherichia coli anti-tumor targeted engineered bacteria EcN (PTEN).

6. The method for constructing the anti-tumor targeted engineered bacterium of Escherichia coli Nissle 1917 according to claim 5, characterized in that: The pten gene sequence is shown in the sequence listing SEQ ID No.

1.

7. The method for constructing the anti-tumor targeting engineered bacterium Escherichia coli Nissle 1917 according to claim 5 or 6, characterized in that: The gene sequence of the hypoxia expression promoter Pvhb is shown in the sequence table SEQ ID No.

2.

8. The method for constructing the anti-tumor targeting engineered bacterium Escherichia coli Nissle 1917 according to claim 5 or 6, characterized in that: The gene sequence of the somo lytic tag is shown in the sequence table SEQ ID No.

3.

9. Use of the anti-tumor targeted engineered bacterium Escherichia coli Nissle 1917 as claimed in claim 1 or 2 in the preparation of anti-tumor targeted drugs.

10. Use of the anti-tumor targeted engineered bacterium Nissle 1917 constructed as claimed in any one of claims 3 to 8 in the preparation of anti-tumor targeted drugs.

Citation Information

Patent Citations

  • Escherichia coli Nissle 1917 anti-tumor targeted engineering bacterial strain as well as construction method and application thereof

    CN109593693A

  • Application of PTEN as immune cell activator in preparation of medicine for treating tumors

    CN118384178A